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underdiagnosis of active TB disease during the ante-
natal and postnatal periods. HIV and TB co-infection 
during pregnancy have a multiplier effect on maternal 
morbidity and mortality, and result in poorer preg-
nancy outcomes.1,11 In Pune, India, TB increased the 
probability of death by 2.2-fold among HIV-infected 
women who developed TB and by 3.4-fold for their in-
fants compared to women who did not develop TB.11 
In Johannesburg, South Africa, 70% of obstetric deaths 
in HIV-infected women were mainly attributed to 
TB.12 These fi gures suggest that routine screening of 
pregnant women for TB in endemic settings would be 
helpful, particularly those who are HIV-infected. 
The World Health Organization (WHO) recom-
mends ruling out active TB and identifying those in 
need of further testing among HIV-infected adults us-
ing specifi c symptoms (current cough of any duration, 
fever, weight loss or night sweats).13 Although these 
recommendations were not specifi c for pregnancy, 
Gupta et al. used this recommendation and found a 
1.4% (11/799) prevalence of active TB among HIV-
i nfected pregnant women who were part of a clinical 
trial in India.14 Another study of cough of >2 weeks, 
performed in Kenya by the same clinical team and by 
the same fi rst author in a routine setting similar to the 
target population for this study, failed to identify 
those with TB disease (n = 187).15 The current study 
differs from the earlier one in its larger sample size and 
because it compares HIV-infected and non-infected 
pregnant women. 
Data on the utilization of symptom screening among 
pregnant women in routine settings are scarce. This 
has been attributed to signifi cant fi nancial and logisti-
cal challenges in the implementation of screening in 
this group of patients.1 The objectives of the present 
study were 1) to explore the utility of TB symptom 
screening using symptoms of ⩾2 weeks’ duration in a 
routine setting, and 2) to compare differences in di-
agnosis of TB among HIV-infected and non-infected 
pregnant women in western Kenya. 
METHODS
Study design
This was a descriptive cohort study among HIV-infected 
and non-infected pregnant women. 
Study site and setting
The study was conducted at the Moi Teaching and Re-
ferral Hospital (MTRH) antenatal care clinic and the 
AMPATH Prevention of Mother-To-Child Transmission 
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Objectives: 1) To explore the utility of tuberculosis (TB) 
symptom screening for symptoms of ⩾2 weeks’ duration 
in a routine setting, and 2) to compare differences in TB 
diagnosis between human immunodeficiency virus (HIV) 
infected and non-HIV-infected pregnant women in west-
ern Kenya. 
Design: Comparative cross-sectional study among preg-
nant women with known HIV status screened for TB from 
2010 to 2012, in Eldoret, western Kenya. 
Results: Of 2983 participants, respectively 34 (1%), 
1488 (50.5%) and 1461 (49.5%) had unknown, positive 
and negative HIV status. The median age was respectively 
30 years (interquartile range [IQR] 26–35) and 26 years 
(IQR 24–31) in HIV-infected and non-infected participants. 
A positive symptom screen was found in respectively 
8% (119/1488) and 5% (67/1461) of the HIV-infected 
and non-infected women. The median CD4 count at en-
rolment was 377 cells/μl (IQR 244–530) for HIV-infected 
women. One non-HIV-infected patient was sputum-
p ositive. For HIV-infected women, TB was presumptively 
treated in 1% (16/1488) based on clinical symptoms and 
chest X-ray. Cumulatively, anti-tuberculosis treatment was 
offered to 0.6% (17/2949) of the participants. 
Conclusion: This study does not seem to demonstrate the 
utility of TB symptom screening questionnaires in a rou-
tine setting among pregnant women, either HIV-infected 
or non-infected, in western Kenya. 
Reduction of tuberculosis (TB) transmission, mor-bidity and mortality relies largely on intensifi ed 
case fi nding, with consequent early initiation of ade-
quate treatment.1,2 This is particularly important 
among pregnant women in resource-limited settings 
where TB is a cause of non-obstetrical (indirect) mater-
nal deaths.3,4 This burden is higher in settings with a 
high prevalence of human immunodefi ciency virus 
(HIV) infection.5,6 Kenya has an adult HIV prevalence 
of 6.2%,7 with an unacceptably high maternal mortal-
ity ratio of 488 per 100 000 live births; 25% of these 
deaths are attributed to indirect causes such as TB, 
anaemia, HIV and malaria.8
TB case notifi cation data are not stratifi ed for preg-
nancy, but women of reproductive age bear a higher 
burden of TB in sub-Saharan Africa than their male 
counterparts.1,9 Data from Western Cape, South Africa, 
indicate that there is a 24.2-fold higher incidence of 
TB disease among infants born to HIV-infected moth-
ers, diagnosed at a mean age of 6 months, than among 
those of HIV-negative mothers.10 This suggests probable 
AFFILIATIONS
1 Department of Obstetrics 
and Gynaecology, Univer-
sity of Nairobi, Nairobi, 
Kenya
2 AMPATH, Eldoret, Kenya
3 The Memorial Hospital of 




4 University of Ghent School 
of Medicine, Ghent, 
Belgium
5 Department of Human 
Anatomy, University of 
Nairobi, Nairobi, Kenya
6 Moi University School of 
Public Health, Eldoret, 
Kenya
7 Operational Research Unit, 
Médecins Sans Frontières 
Operational Centre 
Brussels, Luxembourg
8 Alpert School of Medicine 
at Brown University, Provi-
dence, Rhode Island, USA
CORRESPONDENCE
Rose J Kosgei









TB symptom screening 
questionnaire; HIV; TB 
diagnosis
PHA 2013; 3(4): 294–298
© 2013 The Union
Received 30 August 2013
Accepted 27 September 2013
Public Health Action Screening for TB in pregnancy  295
(PMTCT) clinic in Eldoret, Western Kenya. The AMPATH 
programme, described elsewhere, is housed by the 
MTRH, which is the teaching hospital for the Moi 
University School of Medicine and the second largest 
referral hospital in Kenya, with the largest PMTCT 
programme in western Kenya. HIV-infected pregnant 
women are thus generally referred to this facility for 
care, increasing the proportion of HIV-infected preg-
nant women at the MTRH.16–19
HIV-infected pregnant women were offered ante-
natal and HIV care in the AMPATH clinic, while their 
non-HIV-infected counterparts were offered antenatal 
care in the MTRH clinic. Both clinics are located on 
the MTRH grounds in separate buildings, about 200 m 
apart, and serve a similar patient population. 
TB screening and management
Recommendations by the Kenya National AIDS and 
STI Control Programme were to screen for TB in all 
pregnant mothers at every visit. However, as no pro-
gramme guidelines on how screening should be carried 
out were available, screening for TB in pregnancy was 
opportunistic.20 The AMPATH programme screened 
both HIV-infected and non-infected patients for TB us-
ing a routine six-question symptom screening ques-
tionnaire in its cough monitor programme (Table 1). 
Five years of experience among non-pregnant adult 
population demonstrated a 13% sputum smear-positive 
rate, with 8% of smear-negative adults positive on ei-
ther culture or GeneXpert® MTB/RIF (Cepheid, Sunny-
vale, CA, USA; unpublished programme data). The 
Cough Monitor Programme for pregnant women was 
set up within the AMPATH programme with funding 
from the International Union Against Tuberculosis 
and Lung Disease, Paris, France, between October 2010 
and July 2012, as part of standard routine care in the 
AMPATH and MTRH antenatal care clinics.
The symptom screen questionnaire was adminis-
tered by cough monitors, who were lay staff trained for 
this purpose. A positive response to any of the ques-
tions was regarded as a positive symptom screen, and 
prompted sputum collection from those with produc-
tive cough for TB smear microscopy. The symptom 
screen questionnaire was administered to each patient 
only once. Patients whose microscopy and/or culture 
were positive for Mycobacterium tuberculosis were of-
fered standard anti-tuberculosis treatment per national 
guidelines. The data from the symptom screen ques-
tionnaire were entered into an Excel database for pro-
grammatic use (Microsoft, Redmond, WA, USA).
When the attending clinician had a high clinical 
index of suspicion for TB disease, despite unproductive 
cough or sputum negative for M. tuberculosis, a shielded 
chest X-ray (CXR) was performed based on clinical 
opinion. Based on positive CXR results or suggestive 
clinical symptoms, presumptive anti-tuberculosis treat-
ment was offered for these patients.
HIV screening and management
About 90% of pregnant women in Kenya were 
screened for HIV infection as standard of care, unless 
a woman opted out at the time of the study.21 Women 
at the MTRH were screened according to the national 
HIV screening protocol. 
Population
The population included all pregnant women cared 
for at the AMPATH and MTRH antenatal care clinics 
from October 2010 to July 2012, who were screened 
for TB using the AMPATH symptom screen question-
naire and who had clinical data captured in the cough 
monitor database. Patients with unknown HIV status 
and those admitted to hospital were excluded from 
the analysis. 
Sample size
During the study period, a total of 2983 pregnant 
women received antenatal services at the AMPATH and 
MTRH antenatal clinics; these women formed the 
population of this study.
Data collection and data variables 
Routine clinical data were collected retrospectively. 
There were three sources of data in this study: the 
symptom screening questionnaire database, the TB 
laboratory register and patient fi les. The following 
variables were collected from pregnant women at-
tending the PMTCT and antenatal care clinics who 
were administered the symptom screening question-
naire: age, HIV status, CD4 counts if HIV-infected, TB 
symptoms per the symptom screening questionnaire, 
CXR patterns, sputum obtained (yes/no) and sputum 
microscopy results. 
Data analysis
Data were retrieved from the cough monitor database 
and evaluated for inconsistencies and missing data. 
Where possible, data were corrected from source data. 
Descriptive data were reported, numbers and propor-
tions were stratifi ed by HIV status, and continuous data 
were given as median and interquartile range (IQR) for 
the various subcategories related to TB symptom screen-
ing in each group. 
Ethics
This study was approved by both the Institutional and 
Research Ethics Committee of the MTRH, Moi Univer-
sity School of Medicine, Eldoret, Kenya, as well as the 
Institutional Review Board of Lifespan, Providence, RI, 
USA. Only de-identifi ed data were analysed. No pa-
tient names were recorded, only patient numbers, to 
enable linkage with the laboratory and patient fi les. 
No extra data were collected outside of routine care, 
and confi dentiality was observed at all levels of data 
collection. The study was classifi ed as an audit, and 
hence of minimum risk to participants. 
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TABLE 1 AMPATH symptom screening questionnaire
Cough of ⩾2 weeks
Bloody cough in the past year
Fever of ⩾3 weeks 
Past history of TB diagnosis
History of TB contact in the household
Weight loss/failure to gain weight if pregnant in the past year
TB = tuberculosis.
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RESULTS 
Of 2983 pregnant women enrolled in the study, 34 (1%) had un-
known HIV status and were excluded from the analysis. Of the re-
maining 2949 pregnant women, 1488 (50.5%) were HIV-positive 
and 1461 (49.5%) were HIV-negative (Figure). The median age of 
the HIV-infected and non-HIV-infected women was respectively 30 
(IQR 26–35) and 26 years (IQR 24–31). Of the HIV-infected women, 
1101 had a CD4 count available; the median count at enrolment 
in the PMTCT programme was 377 cells/μl (IQR 244–530).
Of the 1488 HIV-infected women, 119 (8%) had a positive TB 
symptom screen, which was signifi cantly higher than among the 
non-HIV-infected women (5%, 67/1461; P < 0.001). As regards 
specifi c symptoms, 3% (43/1488) had a cough of ⩾2 weeks among 
the HIV-infected group vs. 1% (21/1461) among the non-HIV-
i nfected group (P = 0.014; Table 2). 
Only patients with a productive cough had sputum collected 
for microscopy. Of the HIV-infected and non-infected women 
who had cough of ⩾2 weeks, respectively 27/43 and 15/21 had 
productive cough. One non-HIV-infected patient (1/1461) was 
sputum-positive; none were positive in the HIV-infected group 
(Figure). The non-HIV-infected TB patient had cough, positive 
history of contact with an active TB case and weight loss. 
During the study period, 1% (16/1488) of the women in the 
HIV-infected group were treated for TB presumptively; 14 under-
went CXR and two did not. Table 3 shows the CXR features of pa-
tients treated presumptively for TB. Of the 14 patients with CXR, 
10 had features suggestive of TB (pleural effusion, infi ltrate and 
miliary pattern). 
During the study period, 0.6% (17/2949) of the women were 
treated for TB: 16 presumptively in the HIV-infected group and 
one based on a positive smear microscopy result in the non-HIV-
infected group. Table 4 shows the clinical characteristics of the 
patients treated for TB during the study period. 
DISCUSSION
In this study in western Kenya, a symptom screening question-
naire did not produce a high yield of active TB disease among 
pregnant women, either HIV-infected or non-infected. Although 
some women were identifi ed using screening, the majority did 
not have cough with sputum and could not be evaluated using 
microscopy. CXR in this group with non-productive cough might 
have revealed more positive TB cases; however, CXR was not per-
formed systematically. Most of the cases treated were thus based 
on CXR fi ndings, demonstrating a need for further evaluation of 
this test in pregnant women. Reliance on sputum microscopy 
did not seem to be useful given the low sputum availability. 
There seemed to be little difference in results for HIV-positive and 
-negative women. 
These fi ndings are similar to previous fi ndings in the same tar-
get population, although the earlier study had a smaller sample 
FIGURE Results of TB symptom screening in pregnant women in 
western Kenya, 2010–2012.
TABLE 2 TB symptoms of pregnant women who were positive on 








n (%) P value
Symptom screen-positive 119 (8) 67 (5) <0.001
Symptoms 
 Cough ⩾2 weeks  43 (3) 21 (1) 0.014
 Coughed blood in the past year   2 (0.1)  1 (0.1) 0.779
 Fever ⩾3 weeks  19 (1) 31 (2) 0.128
 Weight loss/failure to gain weight 
in the past year  19 (1) 18 (1) 0.037
 Past history of TB contact in the 
household  36 (2) 15 (1) 0.009
 Past history of TB diagnosis  40 (3)  0 <0.001
TB = tuberculosis; HIV = human immunodeficiency virus.
TABLE 3 CXR patterns for HIV-infected pregnant women treated 







CXR = chest X-ray; HIV = human immunodeficiency virus.
TABLE 4 Clinical characteristics of pregnant women treated for TB 
in western Kenya, 2010–2013 (n = 17)
Age, years, median [IQR]  30 [27–33]
Positive symptom screen 4
Symptoms 
 Cough ⩾2 weeks 4
 Coughed blood in the past year 1
 Productive cough 4
 Fever ⩾3 weeks 1
 Weight loss/failure to gain weight in past year 2
 Past history of TB contact in the household 2
 Past history of TB diagnosis 0
CD4 counts, cells/μl, median [IQR]* 256 [106–302]
* 1 non-HIV-infected patient.
TB = tuberculosis; IQR = interquartile range; HIV = human immunodeficiency virus.
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size (n = 187).15 The fi ndings are surprising, given the fact that 
Kenya is a high burden setting for HIV and TB, with an HIV prev-
alence of 6.2%, and ranks thirteenth among the 22 high TB bur-
den countries globally.7,22 Of the 17 pregnant women treated for 
TB, only one had a positive smear microscopy result. The large 
number of patients reporting unproductive cough, particularly in 
the HIV-infected group, raises concerns that TB diagnosis was per-
haps being missed in this population, as sputum microscopy re-
mains the major diagnostic testing strategy. 
These fi ndings could be attributed to the following fi ve possi-
bilities: 1) the TB symptom screening tool is not sensitive enough 
during pregnancy. In a study in South Africa that documented a 
high prevalence of TB among HIV-infected women (47/1415, 
3.3%), the majority (73%) did not report any TB symptoms.23 
2) Symptoms may be attenuated in people living with HIV, often 
yielding negative results on smear microscopy.24 Participants in 
this study who were treated for TB had a lower CD4 count than 
those who were not treated for TB (256 cells/μl, IQR 106–302 vs. 
377 cells/μl, IQR 244–530). 3) Physiological changes associated 
with pregnancy may mask the symptoms of TB.23 4) There may a 
low prevalence of TB in pregnancy—this is less plausible consider-
ing TB is a major cause of non-obstetrical maternal deaths.3 5) A 
combination of all of the above. 
In our setting, the utility of shielded CXR in screening for TB 
in pregnancy among HIV-infected women needs to be evaluated. 
Of the 17 women treated for TB in this study, 10 had CXR fea-
tures suggestive of TB. Of particular note are two cases who had a 
miliary pattern. This fi nding is consistent with previous fi ndings 
in the same population, where 10/187 patients were presump-
tively treated for TB based on suggestive CXR, three of whom had 
a miliary pattern.15 However, a study in India demonstrated mar-
ginal to no added value of CXR in this group.14
Our study had three major limitations. First, a gold standard 
for TB diagnosis was lacking, and not all patients underwent cul-
ture for TB, CXR or further evaluation other than clinical exami-
nation. Second, the WHO TB symptom screening protocol of 
current cough of any duration, fever, weight loss or night sweats 
was not used because the routine data analysed was from before 
implementation of the WHO recommendation. Third, data on 
antiretroviral use among HIV-positive participants were not col-
lected. However, our large sample size, the fact that MTRH is a 
referral hospital, which meant that our study had an equal pro-
portion of HIV-negative and -positive participants, and the fact 
that this was carried out under routine programme conditions, 
are of value. 
CONCLUSION
This study does not seem to demonstrate the utility of TB symp-
tom screening questionnaires in routine settings among pregnant 
women in Western Kenya. There may, however, be a role of CXR 
in screening for TB among HIV-infected pregnant women. More 
analytical hypothesis-driven studies need to be developed to de-
termine the best screening tool for TB in pregnancy in high HIV-
TB burden, low-resource settings. 
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Objective  :  1) Explorer l’utilité du dépistage des symptômes de tu-
berculose (TB) en utilisant les symptômes d’une durée de ⩾2 se-
maines dans un contexte de routine, et 2) comparer les différences 
en matière de diagnostic de TB entre les femmes enceintes infectées 
ou non par le virus de l’immunodéficience humaine (VIH) dans 
l’Ouest du Kenya.
Schéma  :  Etude transversale comparative chez les femmes enceintes 
dont le statut VIH est connu et dépistées pour TB de 2010 à 2012 à 
Eldoret, Ouest du Kenya.
Résultats  :  Sur 2983 participantes, respectivement 34 (1%), 1488 
(50,5%) et 1461 (49,5%) avaient un statut VIH inconnu, positif et né-
gatif. L’âge médian en années est de 30 (IQR 26–35) et de 26 (IQR 
24–31), respectivement, chez les infectées et les non-infectées par le 
VIH. On a trouvé un dépistage positif sur symptômes respectivement 
chez 8% (119/1488) et 5% (67/1461) chez les infectées et non in-
fectées. Le décompte médian de CD4 lors du recrutement a été de 
377 cellules/μl (IQR 244–530) pour les femmes infectées par le VIH. 
Chez une patiente non-infectée par le VIH, l’examen microscopique 
des crachats à la recherche de la TB a été positif. Pour les femmes in-
fectées par le VIH, la TB a été traitée sur présomption dans 1% (16/ 
1488) en se basant sur les symptômes cliniques et le cliché thoracique. 
De manière cumulative, un traitement pour la TB a été offert à 0,6% 
(17/2949) des participantes. 
Conclusion  :  Cette étude ne semble pas démontrer l’utilité d’un ques-
tionnaire sur symptômes pour le dépistage de la TB dans un contexte 
de routine parmi les femmes enceintes, qu’elles soient ou non infec-
tées par le VIH dans l’Ouest du Kenya.
Objetivos: 1) Explorar la utilidad del cribado sistemático de los sínto-
mas de tuberculosis (TB) en la práctica ordinaria, con base en los sín-
tomas de ⩾2 semanas de duración; y 2) comparar las diferencias en 
el diagnóstico de la TB en las embarazadas que presentan infección 
por el virus de la inmunodeficiencia humana (VIH) y las embarazadas 
exentas de esta infección en Kenia occidental. 
Métodos: Fue este un estudio transversal comparativo de las em-
barazadas con situación conocida frente al VIH, a quienes se admini-
stró un cuestionario de cribado de síntomas de TB entre el 2010 y el 
2012, en Eldoret en Kenia occidental. 
Resultados: De 2983 participantes, 34 mujeres desconocían su situa-
ción frente al VIH (1%), 1488 eran positivas al VIH (50,5%) y 1461 
eran negativas (49,5%). La mediana de la edad fue 30 años (IQR 26–
35) en las mujeres positivas al VIH y 26 años (IQR 24–31) en las mu-
jeres sin infección por el virus. Se obtuvo un cribado positivo de sín-
tomas en 8% de las mujeres infectadas por el VIH (IQR 119–1488) y 
en 5% de las mujeres sin infección (IQR 67–1461). La mediana del re-
cuento de células CD4 en el momento del ingreso al estudio fue 377 
células/μl en las mujeres infectadas por el VIH (IQR 244–530). Una 
mujer negativa para el VIH presentó una baciloscopia de esputo posi-
tiva. En el grupo de mujeres infectadas por el VIH se practicó el trata-
miento por presunción de TB en 1% de los casos (16/1488) con base 
en los síntomas clínicos y la radiografía de tórax. Durante el estudio 
se ofreció tratamiento antituberculoso a 0,6% de las participantes 
(17/2949). 
Conclusión: Los resultados del presente estudio no parecen demo-
strar la utilidad del cuestionario de cribado de síntomas de TB en la 
práctica corriente de atención a las embarazadas, que presenten in-
fección por el VIH o que estén exentas de la infección, en Kenia 
occidental.
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